Key takeaways
Trulicity (dulaglutide) and Wegovy (semaglutide) are both GLP-1 receptor agonists injected once a week and both help lower the risk of heart problems. However, they have different FDA-approved uses. Trulicity is approved for managing Type 2 diabetes in people 10 years and older and for reducing heart-related risks in adults with Type 2 diabetes. Wegovy, on the other hand, is approved for long-term weight management in adults and children 12 years and older with certain BMI criteria and also for reducing heart risks in adults with heart disease and a larger body size. Both are only available as a branded medication. Common side effects for both include nausea and stomach pain, but Wegovy tends to cause more nausea thanTrulicity. Both medications carry a risk of thyroid cancer and pancreatitis, and neither are recommended if you have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2.
